---
title: "Saroglitazar in Primary biliary cholangitis: Product information and disease description"
description: "Formulary evidence on Saroglitazar in Primary biliary cholangitis: Product information and disease description. Covers Product description and Place of product in therapy. 78 evidence topics quoted from 59 sources."
canonical: "https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Saroglitazar in Primary biliary cholangitis: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Orphan designation and FDA approval status

| Field | Quoted record |
| --- | --- |
| Date designated | “01/26/2021” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |

Source: [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=686819)

<a id="topic-2.1.1-2"></a>

##### Fast Track designation

> “has granted “Fast Track Designation” to Saroglitazar Mg”

Source: [Zydus Lifesciences (2020)](https://www.zyduslife.com/public/pdf/pressrelease/Zydus_granted_Fast_Track_Designation_by_the_USFDA_for_Saroglitazar_in_the_treatment_of_patients_with_PBC.pdf)

<a id="topic-2.1.1-3"></a>

##### European orphan status

> “Saroglitazar Mg has received Orphan Status from EMA for PBC”

Source: [Zydus Lifesciences (2024)](https://zyduslife.com/investor/admin/uploads/21/83/Zydus-Announces-Completion-of-Enrolment-for-EPICS-IIITM-Phase-2b-3-trial-evaluating-Saroglitazar-Mg-in-treatment-of-Primary-Biliary-Cholangitis.pdf)

<a id="topic-2.1.1-4"></a>

##### Regulatory status: Under review; NDA submitted by May 2026 and accepted May 2026

> “Ahmedabad, India, 28 May 2026”
> “today announced that the US Food and Drug Administration (US FDA) granted Priority Review to the New Drug Application (NDA) for saroglitazar”
> “The acceptance of our NDA with Priority Review highlights the significant unmet need that exists for patients with PBC”

Source: [Zydus Lifesciences NDA priority review announcement (2026)](https://zyduslife.com/investor/admin/uploads/21/83/Press-Release_Zydus-Therapeutics-NDA-for-Saroglitazar-to-treat.pdf)

> “Transcript of the post results earnings call held on November 4, 2026”
> “So, we currently are, you know, we are on track with our responses. So, November is our current goal date”

Source: [Zydus Lifesciences 4 November earnings call transcript (2026)](https://zyduslife.com/investor/admin/uploads/16/0/Earnings-call-transcript-04-Nov-26.pdf)

<a id="topic-2.1.1-5"></a>

##### FDA review

| Field | Quoted information |
| --- | --- |
| NDA review designation | “Priority Review” |
| PDUFA target action date | “November 27, 2026” |

Source: [Zydus Lifesciences NDA priority review announcement (2026)](https://zyduslife.com/investor/admin/uploads/21/83/Press-Release_Zydus-Therapeutics-NDA-for-Saroglitazar-to-treat.pdf)

<a id="topic-2.1.1-6"></a>

##### Launch: Anticipated in March 2027

> “Transcript of the post results earnings call held on November 4, 2026”
> “November is our current goal date and we are, as I said, our current expectation is to launch in March.”
> “Because obviously, you cannot launch in December at the year end.”

Source: [Zydus Lifesciences 4 November earnings call transcript (2026)](https://zyduslife.com/investor/admin/uploads/16/0/Earnings-call-transcript-04-Nov-26.pdf)

<a id="topic-2.1.1-7"></a>

##### Approvals outside the United States: MASH and MASLD publication

> “approved by the Drug Controller General of India (DCGI), for the treatment of MASH and MASLD in India in 2020.”

Source: [Zydus Lifesciences EVIDENCES-X topline results announcement (2026)](https://zyduslife.com/investor/admin/uploads/21/83/Zydus-Announces-Positive-Topline-Results-from-Completed-EVIDENCES-X-Phase-II%28b%29-Clinical-Trial-of-Saroglitazar-Mg-in-MASH.pdf)

<a id="topic-2.1.1-8"></a>

##### Exact FDA submission date; FDA Advisory Committee meeting date

No evidence found.

Additional sources: [Zydus Therapeutics (2026)](https://www.prnewswire.com/news-releases/zydus-therapeutics-new-drug-application-nda-for-saroglitazar-to-treat-primary-biliary-cholangitis-pbc-granted-priority-review-by-the-us-fda-302784488.html)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Product and sponsor

| Field | Quoted record |
| --- | --- |
| Generic name | “saroglitazar magnesium” |
| Sponsor | “Zydus Therapeutics Inc.” |

Source: [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=686819)

<a id="topic-2.1.2.1-2"></a>

###### Manufacturer: Zydus Therapeutics

> “Zydus Therapeutics’ New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA”

Source: [Zydus Lifesciences NDA priority review announcement (2026)](https://zyduslife.com/investor/admin/uploads/21/83/Press-Release_Zydus-Therapeutics-NDA-for-Saroglitazar-to-treat.pdf)

<a id="topic-2.1.2.1-3"></a>

###### Manufacturer relationship

> “As a subsidiary of Zydus Lifesciences, we have access to strong research, development and manufacturing capabilities.”

Source: [Zydus Therapeutics about us page](https://zydustx.com/about-us/)

<a id="topic-2.1.2.1-4"></a>

###### U.S. brand name

No evidence found.

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational oral tablet

> “Saroglitazar Magnesium 1 mg tablet orally administered once daily in the morning before breakfast without food”

Source: [ClinicalTrials.gov NCT05133336](https://clinicaltrials.gov/study/NCT05133336)

<a id="topic-2.1.2.2-2"></a>

###### MedChemExpress research-reagent safety data sheet

| Field | Quoted information |
| --- | --- |
| Product name | “Saroglitazar (magnesium)” |
| Catalog number | “HY-19937A” |
| CAS number | “1639792-20-3” |
| Identified uses | “Laboratory chemicals, manufacture of substances.” |

Source: [MedChemExpress](https://file.medchemexpress.com/batch_PDF/HY-19937A/Saroglitazar-magnesium-SDS-MedChemExpress.pdf)

<a id="topic-2.1.2.2-3"></a>

###### Zydus finished-product safety data sheet

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### Anticipated U.S. price, wholesale acquisition cost, and annual treatment-cost range

No evidence found.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Mechanistic classification

> “dual PPAR alpha / gamma agonist.”

Source: [Zydus Therapeutics pipeline page](https://zydustx.com/pipeline/)

<a id="topic-2.1.2.4-2"></a>

###### AHFS classification code

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### FDA orphan-designated indication

| Field | Quoted record |
| --- | --- |
| Orphan designation | “Treatment of Primary Biliary Cholangitis (PBC)” |

Source: [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=686819)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Mechanism of action

> “Our lead drug candidate, saroglitazar, is a liver-selective, dual PPAR alpha / gamma agonist.”

Source: [Zydus Therapeutics pipeline page](https://zydustx.com/pipeline/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Nonclinical pharmacology

> “These studies evaluate the efficacy and safety profile of Saroglitazar in preclinical in vitro and in vivo models.”

Source: [Jain et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4492752/)

<a id="topic-2.1.2.6.2-2"></a>

###### Preclinical PPAR transactivation assay in HepG2 cells

| Receptor | Saroglitazar EC50 |
| --- | --- |
| hPPARα | “0.65 pmol/L” |
| hPPARγ | “3 nmol/L” |

Source: [Jain et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4492752/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Pharmacokinetics: healthy volunteers

> “Saroglitazar was not eliminated via the renal route.”
> “The pharmacokinetics of saroglitazar support a once daily dosage schedule.”

Source: [Jani et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3824340/)

<a id="topic-2.1.2.6.3-2"></a>

###### Food effect: healthy volunteers, 4-mg tablet

> “food reduced Cmax (maximum concentration) of saroglitazar by 30%”
> “there is no impact of food on the extent of absorption of saroglitazar.”

Source: [Patel et al. (2018a)](https://pubmed.ncbi.nlm.nih.gov/29022212/)

Additional sources: [Patel et al. (2018b)](https://pubmed.ncbi.nlm.nih.gov/29224415/)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Hepatic impairment: single-dose study

| Population or parameter | Quoted finding |
| --- | --- |
| Mild and moderate hepatic impairment | “did not significantly affect the PK of saroglitazar” |
| Severe hepatic impairment: exposure | “increased 3-fold” |
| Severe hepatic impairment: clearance | “61% lower” |
| Severe hepatic impairment: authors’ qualification | “may require close monitoring or dose adjustments” |

Source: [Lawitz et al. (2023)](https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1339)

<a id="topic-2.1.2.8-2"></a>

###### Cholestatic cirrhosis and renal impairment: moderate hepatic impairment in PBC cirrhosis

> “In moderate HI, exposure was significantly increased by 50.4–85% on days 1 and 28, with 34–46% lower clearance”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="topic-2.1.2.8-3"></a>

###### Cholestatic cirrhosis and renal impairment: single-dose pharmacokinetics in non-cirrhotic cholestatic liver disease and severe renal impairment

> “comparable to matched controls”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="topic-2.1.2.8-4"></a>

###### Pregnancy, lactation, and pediatric use

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Saroglitazar

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Saroglitazar on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Nonclinical drug-interaction study

> “preclinical DDI study is not a substitute for a clinical DDI study and associated label claims”

Source: [Giri et al. (2019)](https://www.sciencedirect.com/science/article/abs/pii/S0928098719300132)

<a id="topic-2.1.2.9.2-2"></a>

###### Clinical drug-interaction studies

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### EPICS-III: active-moiety dose

> “Saroglitazar 0.97 mg administered orally once daily”

Source: [EASL Congress (2026)](https://www.easlcongress.eu/wp-content/uploads/2026/05/Media-Release_scientific-2026_28-May_none-1.pdf)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Investigational administration and treatment duration

> “Saroglitazar Magnesium 1 mg tablet orally administered once daily in the morning before breakfast without food”
> “52 weeks”

Source: [ClinicalTrials.gov NCT05133336](https://clinicaltrials.gov/study/NCT05133336)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Commercialization strategy: earnings-call publication

> “With respect to US on PBC, the company has decided to launch the product on its own.”

Source: [Zydus Lifesciences 19 May earnings call transcript (2026)](https://zyduslife.com/investor/admin/uploads/16/0/Earnings-call-transcript-19-May-26.pdf)

<a id="topic-2.1.2.11-2"></a>

###### Expanded access

> “All expanded access requests must be submitted by the patient’s treating physician”
> “This policy does not guarantee access”

Source: [Zydus Therapeutics expanded access and compassionate use policy](https://zydustx.com/helping-patients/expanded-access-and-compassionate-use-policy/)

<a id="topic-2.1.2.11-3"></a>

###### Commercial patient-assistance program; pharmacy distribution network

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Proposed indication: UDCA combination therapy and monotherapy

| Proposed use | Quoted population |
| --- | --- |
| Combination with UDCA | “adults who have had an inadequate response to UDCA” |
| Monotherapy | “patients unable to tolerate UDCA” |

Source: [Zydus Therapeutics (2026)](https://www.prnewswire.com/news-releases/zydus-therapeutics-new-drug-application-nda-for-saroglitazar-to-treat-primary-biliary-cholangitis-pbc-granted-priority-review-by-the-us-fda-302784488.html)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Saroglitazar on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Saroglitazar-specific effect on quality measures

No evidence found.

<a id="topic-2.1.2.13-2"></a>

###### PBC quality-measure consensus

> “Follow-Up Protocols: Establishing evidence-based intervals for treatment response assessments and long-term monitoring.”

Source: [Alvaro et al. (2025)](https://onlinelibrary.wiley.com/doi/10.1111/liv.70118)

Additional sources: [Liver International (2025)](https://onlinelibrary.wiley.com/doi/10.1111/liv.70400)

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### PPAR-agonist systematic review

> “Based on subgroup analysis, Bezafibrate, Seladelpar, and Saroglitazar significantly reduced GGT levels.”
> “Saroglitazar in one study(s)”

Source: [Saeedian et al. (2025)](https://link.springer.com/article/10.1186/s12876-025-03821-2)

<a id="topic-2.1.2.14-2"></a>

###### Network meta-analysis including saroglitazar

> “Due to the higher incidence of elevated liver enzymes observed with the 4 mg dose, saroglitazar at doses of 2 mg was included.”

Source: [Lin et al. (2024)](https://link.springer.com/article/10.1186/s13643-024-02460-0)

<a id="topic-2.1.2.14-3"></a>

###### PPAR-agonist meta-analysis

> “Eight RCTs involving 869 participants in total were included.”

Source: [Tang et al. (2024)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1432814/full)

<a id="topic-2.1.2.14-4"></a>

###### Comparator network meta-analysis

> “The NMA included three studies, each testing obeticholic acid (OCA), seladelpar or elafibranor versus placebo”

Source: [Giannini et al. (2025)](https://onlinelibrary.wiley.com/doi/10.1111/liv.16222)

<a id="topic-2.1.2.14-5"></a>

###### Second-line therapy network meta-analysis

> “Twelve RCTs comprising 1,540 patients (therapy lengths 12–52 weeks) were included.”
> “PPAR agonists (bezafibrate, seladelpar, elafibranor, saroglitazar)”

Source: [Zhao et al. (2026)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1859342/full)

<a id="topic-2.1.2.14-6"></a>

###### PPAR-targeted therapy review

> “Saroglitazar, a dual PPAR-α/γ agonist, showed no effect on pruritus in phase 2; however, the sample size was small.”

Source: [Schattenberg et al. (2026)](https://onlinelibrary.wiley.com/doi/full/10.1111/apt.70598)

<a id="topic-2.1.2.14-7"></a>

###### Emerging-therapy review

> “This review summarizes the current literature regarding the new and emerging therapies for patients with PBC.”

Source: [Sohal et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42101777/)

Additional sources: [Martins et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41869905/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Etiologic uncertainty and autoimmune mechanisms

> “Experts aren’t sure what causes primary biliary cholangitis.”
> “may trigger an autoimmune reaction”

Source: [National Institute of Diabetes and Digestive and Kidney Diseases symptoms and causes page](https://www.niddk.nih.gov/health-information/liver-disease/primary-biliary-cholangitis/symptoms-causes)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Primary biliary cholangitis

<a id="topic-2.2.1.2.1-1"></a>

###### Regional U.S. incidence

> “for an overall age- and sex-standardized incidence of 4.9 cases per 100,000 person-years.”

Source: [Kanth et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5573520/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Primary biliary cholangitis

<a id="topic-2.2.1.2.2-1"></a>

###### U.S. prevalence

> “The adjusted 2021 PBC prevalence was 40.9 per 100,000 adults.”
> “for an estimated total of 105,506 adults with PBC in the United States”

Source: [Levy et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11999412/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### ALP and bilirubin as prognostic markers

> “Combining levels of alkaline phosphatase and bilirubin increased the ability to predict patient survival times.”

Source: [Lammers et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25160979/)

<a id="topic-2.2.1.3-2"></a>

###### Ten-year survival by ALP level one year after study enrollment

| ALP category | Reported ten-year survival |
| --- | --- |
| At or below 2.0 times ULN | “alkaline phosphatase levels ≤ 2.0 times the ULN, 84% survived for 10 years” |
| Above 2.0 times ULN | “62% of those with levels >2.0 times the ULN” |

Source: [Lammers et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25160979/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Small bile-duct injury

> “Primary biliary cholangitis is a chronic disease in which the small bile ducts in the liver become inflamed and are eventually destroyed.”

Source: [National Institute of Diabetes and Digestive and Kidney Diseases definition and facts page](https://www.niddk.nih.gov/health-information/liver-disease/primary-biliary-cholangitis/definition-facts)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Diagnostic considerations

> “Liver biopsy is not required for the diagnosis of PBC in patients with cholestasis and PBC-specific autoantibodies”

Source: [You et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10037524/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Constitutional symptoms: fatigue

> “The most common symptoms of primary biliary cholangitis are”
> “feeling tired”

Source: [National Institute of Diabetes and Digestive and Kidney Diseases symptoms and causes page](https://www.niddk.nih.gov/health-information/liver-disease/primary-biliary-cholangitis/symptoms-causes)

<a id="topic-2.2.1.6-2"></a>

###### Dermatologic symptoms: pruritus

> “itchy skin”

Source: [National Institute of Diabetes and Digestive and Kidney Diseases symptoms and causes page](https://www.niddk.nih.gov/health-information/liver-disease/primary-biliary-cholangitis/symptoms-causes)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Hepatic and extrahepatic complications

| Complication domain | Quoted condition |
| --- | --- |
| Fibrosis | “Cirrhosis” |
| Vascular | “Portal hypertension” |
| Hepatic function | “liver failure” |
| Malignancy | “liver cancer” |
| Skeletal | “osteoporosis” |
| Nutritional | “low levels of fat-soluble vitamins A, D, E, and K” |

Source: [National Institute of Diabetes and Digestive and Kidney Diseases definition and facts page](https://www.niddk.nih.gov/health-information/liver-disease/primary-biliary-cholangitis/definition-facts)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Primary biliary cholangitis

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### ITCH-E study: full journal publication

> “The MSP group reported significantly greater activity impairment due to PBC (57%) than the NMP group (36%; p < 0.001).”

Source: [Levy et al. (2025c)](https://onlinelibrary.wiley.com/doi/full/10.1111/liv.70276)

<a id="topic-2.2.1.8.1-2"></a>

###### Pruritus and work productivity

> “a positive association between pruritus severity and work hours lost among employed adults with PBC”

Source: [Levy et al. (2025b)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2025/poster-session-5/assessing-the-relationship-between-pruritus-and-work-productivity-among-individuals-with-pbc-and-pruritus-results-from-the-itch-e-study)

<a id="topic-2.2.1.8.1-3"></a>

###### TARGET-PBC: pruritus and treatment patterns

> “Patients reporting clinically significant pruritus were more likely to receive treatment, but 33% had never received treatment”

Source: [Mayo et al. (2023)](https://link.springer.com/article/10.1007/s10620-022-07581-x)

<a id="topic-2.2.1.8.1-4"></a>

###### Validation of pruritus and patient-reported outcome instruments

> “Convergent, discriminant, and known-groups validity were confirmed for all three NRS items and the PBC-40.”

Source: [Gelhorn et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12315290/)

Additional sources: [Elman et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2875190/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### U.S. inpatient costs by treatment line

> “Patients in the untreated cohort had the highest mean IP costs during the follow-up period (untreated: $37,974; 1L: $5854; 2L+: $6898).”

Source: [Kumar et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12909387/)

<a id="topic-2.2.1.8.2-2"></a>

###### Pruritus-associated healthcare utilization and costs

> “one-year adjusted healthcare costs averaged $39 949 for pruritus and $25 695 for controls”

Source: [Gish et al. (2026)](https://onlinelibrary.wiley.com/doi/full/10.1002/lci2.70044)

<a id="topic-2.2.1.8.2-3"></a>

###### Fatigue or pruritus: matched case-control study

> “total healthcare costs (mean cost difference: fatigue, $42,515; pruritus $40,536).”

Source: [Kumar et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556923/)

<a id="topic-2.2.1.8.2-4"></a>

###### Population-based cost-of-illness study

> “The economic burden of Primary Biliary Cholangitis (PBC) has not been investigated at population-level.”

Source: [Gerussi et al. (2021)](https://www.sciencedirect.com/science/article/abs/pii/S159086582030387X)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Primary biliary cholangitis on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Modeled informal-caregiver productivity losses

> “Approximately 6.4% of the societal and 8.1% of the fiscal consequences related to caregiver productivity losses.”

Source: [Martins et al. (2026b)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-1-4/beyond-the-health-sector-estimating-the-societal-and-fiscal-impact-of-primary-biliary-cholangitis-in-the-united-states)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

No evidence found.

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Hydrophilic Bile Acids

<a id="topic-2.2.2.1.1-1"></a>

###### First-line treatment

> “UDCA at a dose of 13 to 15 mg/kg/day is the first-line therapy for PBC.”

Source: [AASLD (2018)](https://www.aasld.org/sites/default/files/2022-04/PracticeGuidelines-PBC-November2018_1.pdf)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Peroxisome Proliferator-Activated Receptor Agonists

<a id="topic-2.2.2.1.2-1"></a>

###### Comparator prescribing information: elafibranor

> “The recommended dosage is 80 mg orally once daily with or without food.”

Source: [FDA IQIRVO prescribing information](https://www.fda.gov/media/180873/download)

<a id="topic-2.2.2.1.2-2"></a>

###### Comparator prescribing information: seladelpar

> “The recommended dosage of LIVDELZI is 10 mg orally once daily.”
> “Administer LIVDELZI with or without food.”

Source: [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)

Additional sources: [Dalekos et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004822/); [Aghemo et al. (2026)](https://www.sciencedirect.com/science/article/pii/S1590865826007851)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Fibrates

<a id="topic-2.2.2.1.3-1"></a>

###### Fibrates

> “Fibrates can be considered as off-label alternatives for patients with PBC and inadequate response to ursodeoxycholic acid, although fibrates are discouraged in patients with decompensated liver disease.”

Source: [AASLD (2021)](https://pubmed.ncbi.nlm.nih.gov/34431119/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Bile Acid Sequestrants

<a id="topic-2.2.2.1.4-1"></a>

###### Pruritus: first-line pharmacologic treatment

> “cholestyramine as first-line treatment”

Source: [Dalekos et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004822/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Rifamycins

<a id="topic-2.2.2.1.5-1"></a>

###### Pruritus: second-line pharmacologic treatment

> “rifampicin as second-line treatment”

Source: [Dalekos et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004822/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Ileal Bile Acid Transporter Inhibitors

<a id="topic-2.2.2.1.6-1"></a>

###### Linerixibat: FDA approval for cholestatic pruritus

> “has approved Lynavoy (linerixibat) for the treatment of cholestatic pruritus in adult patients with PBC.”

Source: [GSK (2026)](https://www.gsk.com/en-gb/media/press-releases/lynavoy-linerixibat-approved-by-the-us-fda/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Opioid Antagonists

<a id="topic-2.2.2.1.7-1"></a>

###### Pruritus: naltrexone

> “particularly naltrexone”

Source: [Dalekos et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004822/)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Selective Serotonin Reuptake Inhibitors

<a id="topic-2.2.2.1.8-1"></a>

###### Pruritus: sertraline

> “Selective serotonin reuptake inhibitors, such as sertraline”

Source: [Dalekos et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004822/)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Supportive and Nonpharmacological Care

<a id="topic-2.2.2.1.9-1"></a>

###### Fatigue: nonpharmacological care

> “coping strategies and physical activities”

Source: [Dalekos et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004822/)

<a id="topic-2.2.2.1.9-2"></a>

###### Prevention of skeletal complications

> “dietary supplements of calcium and vitamin D.”

Source: [National Institute of Diabetes and Digestive and Kidney Diseases (2021)](https://www.niddk.nih.gov/health-information/liver-disease/primary-biliary-cholangitis/treatment)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 Liver Transplantation

<a id="topic-2.2.2.1.10-1"></a>

###### Liver failure

> “If cirrhosis leads to liver failure, you may need a liver transplant.”

Source: [National Institute of Diabetes and Digestive and Kidney Diseases (2021)](https://www.niddk.nih.gov/health-information/liver-disease/primary-biliary-cholangitis/treatment)

<a id="heading-2.2.2.1.11"></a>

###### 2.2.2.1.11 Limitations of Current Therapies

<a id="topic-2.2.2.1.11-1"></a>

###### Summary

UDCA is first-line treatment, while fibrates remain off-label alternatives and are discouraged in decompensated liver disease. The seladelpar prescribing information states that improved survival or prevention of liver decompensation has not been demonstrated. Obeticholic acid is no longer a current U.S. option: FDA withdrawal of approval took effect on November 24, 2025. Symptom management also remains incomplete; in TARGET-PBC, 33% of participants reporting clinically significant pruritus had never received treatment for it.

Source: [AASLD (2018)](https://www.aasld.org/sites/default/files/2022-04/PracticeGuidelines-PBC-November2018_1.pdf); [AASLD (2021)](https://pubmed.ncbi.nlm.nih.gov/34431119/); [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf); [FDA (2025)](https://www.govinfo.gov/content/pkg/FR-2025-11-24/pdf/2025-20767.pdf); [Mayo et al. (2023)](https://link.springer.com/article/10.1007/s10620-022-07581-x)

<a id="topic-2.2.2.1.11-2"></a>

###### Seladelpar: clinical-outcome limitation

> “Improvement in survival or prevention of liver decompensation events have not been demonstrated.”

Source: [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)

<a id="topic-2.2.2.1.11-3"></a>

###### Obeticholic acid: U.S. withdrawal announcement

> “today announced its decision to voluntarily withdraw OCALIVA® (obeticholic acid) from the US market”

Source: [Intercept Pharmaceuticals (2025)](https://www.globenewswire.com/news-release/2025/09/11/3148535/23024/en/Intercept-Announces-Voluntary-Withdrawal-of-OCALIVA-for-Primary-Biliary-Cholangitis-PBC-from-the-US-Market-US-Clinical-Trials-Involving-Obeticholic-Acid-Placed-on-Clinical-Hold.html)

<a id="topic-2.2.2.1.11-4"></a>

###### Obeticholic acid: withdrawal of FDA approval

> “Approval is withdrawn as of November 24, 2025.”

Source: [FDA (2025)](https://www.govinfo.gov/content/pkg/FR-2025-11-24/pdf/2025-20767.pdf)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

The proposed U.S. indication positions saroglitazar as combination treatment with UDCA in adults with an inadequate response, or as monotherapy in patients unable to tolerate UDCA. This is a proposed indication, not an approved prescribing recommendation. PBC management consensus includes referral to a centre with specific clinical and research expertise in PBC. The expanded-access policy requires requests from the treating physician and does not guarantee access.

Source: [Zydus Therapeutics (2026)](https://www.prnewswire.com/news-releases/zydus-therapeutics-new-drug-application-nda-for-saroglitazar-to-treat-primary-biliary-cholangitis-pbc-granted-priority-review-by-the-us-fda-302784488.html); [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=686819); [Alvaro et al. (2025)](https://onlinelibrary.wiley.com/doi/10.1111/liv.70118); [Zydus Therapeutics expanded access and compassionate use policy](https://zydustx.com/helping-patients/expanded-access-and-compassionate-use-policy/)

Additional sources: [Shamseddine et al. (2026)](https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-clinical-outcomes-of-patients-with-primary-biliary-cholangitis-in-the-united-states/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### EPICS-III: subgroup defined by baseline ALP

| Subgroup or outcome | Quoted value |
| --- | --- |
| Baseline ALP threshold | “≤ 3 x ULN” |
| Saroglitazar biochemical response | “83.1%” |
| Placebo biochemical response | “14.7%” |

Source: [Zydus Therapeutics (2026)](https://www.prnewswire.com/news-releases/zydus-therapeutics-new-drug-application-nda-for-saroglitazar-to-treat-primary-biliary-cholangitis-pbc-granted-priority-review-by-the-us-fda-302784488.html)

<a id="topic-2.2.2.3-2"></a>

###### PPAR-agonist systematic review: between-study heterogeneity

> “we encountered a wide between-study heterogeneity”

Source: [Saeedian et al. (2025)](https://link.springer.com/article/10.1186/s12876-025-03821-2)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Referral to PBC expertise

> “Referral to a centre with specific clinical and research expertise in PBC”

Source: [Alvaro et al. (2025)](https://onlinelibrary.wiley.com/doi/10.1111/liv.70118)

<a id="topic-2.2.2.4-2"></a>

###### Risk-stratified follow-up intervals

| Risk category | Quoted interval |
| --- | --- |
| Intermediate or high risk of disease progression: at least | “every 6 months” |
| Low risk of disease progression: at least | “once a year” |

Source: [Alvaro et al. (2025)](https://onlinelibrary.wiley.com/doi/10.1111/liv.70118)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### ALP and bilirubin: surrogate outcomes

> “might be used as surrogate end points in therapy trials.”

Source: [Lammers et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25160979/)

<a id="topic-2.2.2.7-2"></a>

###### Surrogate endpoints and real-world evidence: Delphi consensus statement

> “The Delphi process resulted in agreement on 16 statements and 42 recommendations across the three thematic domains.”

Source: [EASL-AASLD (2026)](https://pubmed.ncbi.nlm.nih.gov/42191456/)

## Related pages
- [Saroglitazar: Primary biliary cholangitis](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis.md)
- [Saroglitazar in Primary biliary cholangitis: Terms and abbreviations](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/terms-and-abbreviations.md)
- [Saroglitazar: Primary biliary cholangitis](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/executive-summary.md)
- [Saroglitazar in Primary biliary cholangitis: Clinical evidence](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/clinical-evidence.md)
- [Saroglitazar in Primary biliary cholangitis: Economic information and modeling report](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/economics) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/economics.md)
- [Saroglitazar in Primary biliary cholangitis: References](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/references) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/references.md)
- [Saroglitazar in Primary biliary cholangitis: prevalence by geography](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/prevalence) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/prevalence.md)
- [Saroglitazar in Primary biliary cholangitis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/cost-effectiveness-analyses.md)
